191 related articles for article (PubMed ID: 31032431)
1. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
Takahashi H; Nomiyama T; Terawaki Y; Horikawa T; Kawanami T; Hamaguchi Y; Tanaka T; Motonaga R; Fukuda T; Tanabe M; Yanase T
Biochem Biophys Rep; 2019 Jul; 18():100640. PubMed ID: 31032431
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
Terawaki Y; Nomiyama T; Kawanami T; Hamaguchi Y; Takahashi H; Tanaka T; Murase K; Nagaishi R; Tanabe M; Yanase T
Cardiovasc Diabetol; 2014 Nov; 13():154. PubMed ID: 25407968
[TBL] [Abstract][Full Text] [Related]
3. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
Jojima T; Tomotsune T; Iijima T; Akimoto K; Suzuki K; Aso Y
Diabetol Metab Syndr; 2016; 8():45. PubMed ID: 27462372
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2
Fujita H; Otomo H; Takahashi Y; Yamada Y
Biochem Biophys Res Commun; 2022 Dec; 635():84-91. PubMed ID: 36265286
[TBL] [Abstract][Full Text] [Related]
8. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
[TBL] [Abstract][Full Text] [Related]
9. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
Chen L; Klein T; Leung PS
Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.
Dutzmann J; Bode LM; Kalies K; Korte L; Knöpp K; Kloss FJ; Sirisko M; Pilowski C; Koch S; Schenk H; Daniel JM; Bauersachs J; Sedding DG
Front Cardiovasc Med; 2022; 9():956041. PubMed ID: 36017090
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Rizos CV; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
13. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
Ma M; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Nakagawa T; Lin B; Kim-Mitsuyama S
Cardiovasc Diabetol; 2015 May; 14():54. PubMed ID: 25986579
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats.
Zhang WX; Tai GJ; Li XX; Xu M
Free Radic Biol Med; 2019 Nov; 143():153-163. PubMed ID: 31369842
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X; Hu J
Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Jain RK
Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
[TBL] [Abstract][Full Text] [Related]
17. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Gallwitz B
Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
Sharkovska Y; Reichetzeder C; Alter M; Tsuprykov O; Bachmann S; Secher T; Klein T; Hocher B
J Hypertens; 2014 Nov; 32(11):2211-23; discussion 2223. PubMed ID: 25215436
[TBL] [Abstract][Full Text] [Related]
19. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
20. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]